Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Webster

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
The Health Service Journal|September 2, 2014
The NHS has to shape its own futureRob Webster
The Health Service Journal|July 27, 2018
On Washing Away The Stain of BullyingRob Webster
BMJ (Clinical Research Ed.)|April 18, 2015
It's time to be honest about NHS funding for the next five yearsRob Webster
The Health Service Journal|February 27, 2013
Aspirations of greatnessRob Webster
Advances in Pharmacology (San Diego, Calif.)|July 11, 2012
Disposition of biologicsKevin Brady, Rob Webster
Current Opinion in Drug Discovery & Development|February 28, 2002
Towards a drug concentration effect relationship for QT prolongation and torsades de pointesRob Webster, Derek Leishman, Don Walker
Journal of Feline Medicine and Surgery|October 11, 2017
Clinical presentations, treatments and risk factors for mortality in cats with tick paralysis caused by Ixodes holocyclus: 2077 cases (2008-2016)Ellie Leister, John Morton, Rick Atwell, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 6, 2006
PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studiesRob Webster, Eric Didier, Philip Harris, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 16, 2007
Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonistsAlison Betts, Fidelma Atkinson, Iain Gardner, et al.
The AAPS Journal|April 13, 2019
Induction and Impact of Anti-Drug Responses Elicited by a Human Recombinant Coagulation Factor FXa<sup>I16L</sup> in Preclinical SpeciesChuenlei Parng, Michael Bolt, Debra D Pittman, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
The Health Service Journal|September 2, 2014
The NHS has to shape its own futureRob Webster
The Health Service Journal|July 27, 2018
On Washing Away The Stain of BullyingRob Webster
BMJ (Clinical Research Ed.)|April 18, 2015
It's time to be honest about NHS funding for the next five yearsRob Webster
The Health Service Journal|February 27, 2013
Aspirations of greatnessRob Webster
Advances in Pharmacology (San Diego, Calif.)|July 11, 2012
Disposition of biologicsKevin Brady, Rob Webster
Current Opinion in Drug Discovery & Development|February 28, 2002
Towards a drug concentration effect relationship for QT prolongation and torsades de pointesRob Webster, Derek Leishman, Don Walker
Journal of Feline Medicine and Surgery|October 11, 2017
Clinical presentations, treatments and risk factors for mortality in cats with tick paralysis caused by Ixodes holocyclus: 2077 cases (2008-2016)Ellie Leister, John Morton, Rick Atwell, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 6, 2006
PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studiesRob Webster, Eric Didier, Philip Harris, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 16, 2007
Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonistsAlison Betts, Fidelma Atkinson, Iain Gardner, et al.
The AAPS Journal|April 13, 2019
Induction and Impact of Anti-Drug Responses Elicited by a Human Recombinant Coagulation Factor FXa<sup>I16L</sup> in Preclinical SpeciesChuenlei Parng, Michael Bolt, Debra D Pittman, et al.
Pageof 3